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Abstract
Objective To identify factors that mediate or moderate
the effects of exercise on postmenopausal sex hormone
concentrations.
Methods Postmenopausal women were randomized to
12 months of aerobic exercise for 200 min/week (n = 160)
or to a control group (n = 160). Intention-to-treat analyses
were performed using general linear models with sex
hormone concentrations at 6 and 12 months as the out-
come. Mediation by adiposity and insulin was investigated
by examining changes in effect estimates after adjustment
for changes in these factors over 12 months. Moderation
was studied as the interaction between group assignment
and eight baseline characteristics.
Results Intervention effects on sex hormone–binding
globulin (SHBG) and estradiol changes were attenuated
with adjustment for change in overall body fat, while there
was less attenuation adjusting for intra-abdominal fat
change. Intervention effects on SHBG levels were unaf-
fected by adjustment for insulin change. Signiﬁcant inter-
actions were identiﬁed between treatment and physical
ﬁtness (for SHBG and testosterone) and age (for testoster-
one), implying subgroup differences in intervention effect.
Conclusions Our data suggest that overall fat loss par-
tially mediated exercise-induced changes in estradiol and
SHBG concentrations. No previous RCT in postmeno-
pausal women has studied moderators of exercise-induced
sex hormone changes; therefore, future studies are needed
to corroborate our results.
Keywords Exercise  Gonadal steroid hormones 
Sex hormone–binding globulin  Randomized controlled
trial  Breast neoplasms
Introduction
A wealth of epidemiologic evidence supports a preventive
role for physical activity in postmenopausal breast
cancer etiology, but the biologic changes mediating this
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DOI 10.1007/s10552-011-9809-5association remain poorly understood [1, 2]. Two plausible
mechanisms are a decrease in sex hormone concentrations
and an increase in sex hormone–binding globulin (SHBG)
concentrations, which are convincingly associated with
postmenopausal breast cancer risk [3]. As adipose tissue is
the main source of sex hormones in postmenopausal
women, exercise-induced fat loss could drive changes in
their levels [4]. Exercise-induced reductions in insulin
could increase SHBG synthesis in the liver [5].
It is also unclear whether any factors moderate the
association between physical activity and postmenopausal
breast cancer risk. Although the epidemiologic evidence
suggests that the relationship between physical activity
and reduced postmenopausal breast cancer risk is proba-
ble [1, 2], there is variability across studies in the mag-
nitude of the association, possibly attributable to subgroup
differences in the study populations deﬁned by factors
such as age and BMI [1]. These factors, and others, may
also modify the effects of physical activity on sex hor-
mone or SHBG levels, perhaps because they relate to
baseline levels of sex hormones and SHBG (high baseline
levels may result in a ceiling effect whereby exercise will
not result in further increase; low baseline levels may
result in a ﬂoor effect whereby exercise will not result in
further decrease) or because they relate to exercise
adherence.
The Alberta Physical Activity and Breast Cancer Pre-
vention (ALPHA) Trial was a randomized controlled trial
(RCT) designed to determine the effects of a 12-month
aerobic exercise intervention on proposed biomarkers of
postmenopausal breast cancer risk. We previously repor-
ted that, relative to controls, postmenopausal women
assigned to the intervention experienced signiﬁcantly
greater decreases in circulating total and free estradiol
[6], circulating insulin [7], and total and abdominal fat [8]
and signiﬁcantly greater increases in SHBG levels [6].
Because clarifying the biologic mechanisms through
which exercise induces sex hormone and SHBG changes
and distinguishing subgroups of women in whom exercise
may have a stronger effect on sex hormone and SHBG
changes could help inform public health recommenda-
tions for lowering postmenopausal breast cancer risk, we
present here a secondary analysis of ALPHA Trial data
using analytic techniques described by Kraemer et al. [9]
and Mackinnon and Fairchild [10] to (1) explore adi-
posity and insulin changes as potential mediators of the
exercise-induced estradiol and SHBG changes we
observed and (2) examine baseline characteristics as
potential moderators of the intervention effect on changes
in estradiol, estrone, testosterone, and SHBG, which are
all convincingly associated with postmenopausal breast
cancer risk [3].
Materials and methods
Study population
The ALPHA Trial study population and recruitment details
have been described previously [6, 8]. Inactive women
(\90 min/week recreational activity over the past year or,
if between 90 and 120 min/week of physical activity had a
VO2max\34.5 mL/kg/min), aged 50–74 years, postmen-
opausal for at least 24 months, body mass index (BMI)
22–40 kg/m
2, with no major co-morbidities or previous
cancer diagnosis besides non-melanotic skin cancer, were
recruited from the general population in Calgary and Ed-
monton, Alberta, Canada. Eligibility criteria also included
the following: English-speaking, acceptable heart and lung
function as assessed by a baseline ﬁtness test, able to
undertake unrestricted physical activity as assessed by their
physician [11], normal levels of fasting lipids, glucose,
thyroid-stimulating hormone and alanine aminotransferase,
breast tissue density above a zero density level, non-dia-
betic, non-smoker, alcohol intake \14 drinks/week, no
medications or exogenous hormones that might inﬂuence
estrogen metabolism and not currently or planning to
undertake a weight loss program or planning any extended
absences in the 18 months subsequent to enrollment.
Intervention
The study participants were randomly allocated either to a
year-long, moderate-to-vigorous-intensity, aerobic exercise
intervention (n = 160) or to a control group (n = 160)
assigned to no exercise. Details of randomization have been
described previously [6]. The exercise intervention was
individually prescribed program of at least 45 min of any
typeofaerobicexercisedone5 daysperweekfor12 months
at70–80%heartratereserve.Atleastthreesessionsperweek
were supervised by exercise trainers at our ﬁtness centers,
and the rest were home-based. The frequency, duration, and
intensity were gradually increased during the ﬁrst 3 months
of the intervention from 3 weekly sessions of 15- to 20-min
duration at an intensity of 50–60% heart rate reserve to the
ﬁnalprescriptionachievedinweek12.Womeninthecontrol
group were asked to maintain their regular inactive lifestyle.
No changes to usual dietary intake were to be made in either
group.EthicsapprovalwasobtainedfromtheAlbertaCancer
Board and Universities of Calgary and Alberta, and all par-
ticipants provided written informed consent.
Measurements
Baseline data on demographics, medical and medication
history, self-rated health, and past year physical activity
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Anthropometric measurements were taken in duplicate; if
the two measurements were discrepant (i.e., not identical),
a third measurement was taken and the average of the two
closest was used in the analyses. Weight and height mea-
surements were taken using a balance beam scale and a
stadiometer. Body mass index was calculated as weight/
height
2 (kg/m
2). At baseline and 12 months, total body fat
and body fat percentage were measured using whole-body
dual X-ray absorptiometry scans. In Calgary, scans were
done on a Hologic QDR 4500 W
 scanner in whole-body
mode and analyzed with software version 11.2.1 (Holog-
ic
, Inc., Bedford, MA, USA). In Edmonton, scans were
done on a Lunar Prodigy
 scanner in either standard mode
or thick mode and analyzed with enCORE Software
6.70.01 before November 2004 and 8.60 after November
2004 (Lunar
 General Electric Medical Systems, Madison,
WI, USA). Percent body fat was calculated as 100% 9 {fat
mass/(fat mass ? lean mass)}. Intra-abdominal fat was
measured with a single computed tomography slice at the
umbilicus. In Calgary, scans were done using a Marconi
PQ5000 VisionMaster/Picker, and in Edmonton, using a
Phillips/Marconi MX8000 multislice scanner. The study
radiologist used an image analysis software program
(Phillips Medical Systems PQ5000) to identify and
demarcate the thresholds between the subcutaneous and
intra-abdominal area. Physical ﬁtness was assessed at
baseline and 12 months using a modiﬁed Balke treadmill
protocol to estimate maximum oxygen consumption
(VO2max) from submaximal exercise intensities. Oxygen
consumption at the age-predicted maximum heart rate was
estimated by extrapolating from the two last completed
stages using the American College of Sports Medicine
metabolic equations for estimating oxygen consumption at
the workload of each stage [13].
Blood was collected after a minimum 10-h fast at
baseline (60 mL), 6 and 12 months (40 mL), and medica-
tions taken in the past 24 h were recorded. Participants
were asked not to exercise for 24 h pre-blood draw. All
blood samples were collected, processed, and stored within
12 h of collection and then shipped and stored in -86C
freezers until time of assay. Analyses were conducted by
the Reproductive Endocrine Research Laboratory at the
University of Southern California, a laboratory with well-
established protocols and quality control procedures.
Serum estradiol and testosterone levels were quantiﬁed by
radioimmunoassay after organic solvent extraction and
Celite column partition chromatography [14–16]. Chro-
matographic separation of the steroids was achieved by
using different concentrations of toluene in iso-octane and
ethyl acetate in iso-octane. Sex hormone–binding globulin
(SHBG) and insulin were quantiﬁed via chemiluminescent
immunometric assay using the Immulite Analyzer
(Siemens Healthcare Diagnostics, Deerﬁeld, IL). The
SHBG concentration and an assumed albumin concentra-
tion of 43 g/L were then utilized in a validated algorithm
with total estradiol to calculate free estradiol [17].
Hypothesized mediators and moderators
Our hypothesized mediators were body fat change (for sex
hormones and SHBG) and circulating insulin change (for
SHBG). These hypotheses were supported by our earlier
review of the scientiﬁc literature on proposed biologic
mechanisms relating physical activity to postmenopausal
breast cancer risk [4]. Moreover, the proposed mediators,
by deﬁnition [9], were associated with our exercise inter-
vention; relative to controls, the exercise group in the
ALPHA Trial experienced signiﬁcantly greater decreases
in total body fat, intra-abdominal fat area [8], and circu-
lating insulin levels [7] over 12 months.
Potential moderators were baseline characteristics for
ALPHA Trial participants that were selected for their
hypothetical relations either to exercise adherence during
the trial (e.g., baseline ﬁtness level, age, years postmeno-
pause, self-rated health, previous recreational activity,
baseline BMI) or to changes in sex hormone levels (e.g.,
circulating levels of sex hormones at baseline, previous
HRT use, baseline BMI). We hypothesized that women
who exercised more might experience greater changes in
sex hormone levels and that women with higher sex hor-
mone levels or lower SHBG levels at baseline might
experience greater changes as a result of the exercise
intervention.
Statistical analyses
The analyses included participants with complete data and
were based on assigned groups at randomization regardless
of adherence. Hormone levels were log-transformed to
achieve an approximate symmetric distribution. Interven-
tion effects were evaluated with general linear models
considering the repeated measures of sex hormone con-
centrations at 6 and 12 months. The model took the fol-
lowing form: Yij = b0 ? b1 Xi ? cZij ? eij, where, for the
ith subject, Yij is a log-transformed outcome measure at jth
time (j = 1 for 6 months, j = 2 for 12 months), Xi is an
indicator variable for the exercise intervention arm (0 for
control, 1 for exercise intervention), Zij is a vector of
adjustment variables, and (ei1, ei2) is a correlated error
vector following a bivariate Gaussian distribution with
mean 0. Of the parameters b0, b1, and c (associated with
the intercept, exercise intervention, and adjustment vari-
ables, respectively), b1 is the target parameter, representing
the adjusted difference in the mean log outcome between
the exercise intervention group and the control group over
Cancer Causes Control (2011) 22:1365–1373 1367
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the exponential of b1 as the treatment effect ratio (TER), as
it is a ratio of the adjusted geometric means of the outcome
for the exercise intervention group over the control group.
In this paper, we also refer to the TER as the ‘intervention
effect’.
Our assessment of mediation was based on ﬁndings
from the general linear model with both the intervention
assignment and changes in the hypothesized mediators
predicting changes in sex hormone or SHBG levels.
Mediation by adiposity and insulin levels was investigated
in two ways. Primarily, mediation was investigated by
examining the change in the TER pre- versus postad-
justment for changes in the hypothesized mediators at 6
and 12 months from baseline. If the adjustment attenuated
TER, then we considered this ﬁnding to be suggestive of
mediation [10]. Secondarily, the main effect of each
potential mediator on sex hormone or SHBG changes was
also evaluated in these models, adjusting for the inter-
vention assignment. Kraemer et al. [9] explain that a
mediator must measure a change occurring during treat-
ment (e.g., changes in body fat and insulin levels occurred
during the 12-month intervention period [7, 8]), must
correlate with treatment assignment (e.g., we observed
signiﬁcantly greater changes in body fat and insulin levels
in the exercise group than in controls [7, 8]), and must
have either a main or interactive effect on the outcome.
This secondary analysis is informative because it is these
conditions under which our main analysis would suggest
mediation.
Moderation was investigated by determining the sta-
tistical signiﬁcance of the interaction term between the
intervention assignment and each hypothesized moderator
(described above), adjusting for the baseline outcome
(e.g., baseline estradiol level), the intervention group
assignment, time, and the hypothesized moderator (e.g.,
baseline age) [9]. All baseline characteristics were treated
as continuous variables in these analyses with the
exception of HRT use, which was dichotomized. To help
explain our ﬁndings from these analyses, intervention
effects were also estimated within subgroups of these
characteristics. We reported intervention effects within all
subgroups regardless of the statistical signiﬁcance of the
interaction term in general linear models. Subgroups were
created by dichotomizing each variable at the median
with the exception of self-rated health, which was mea-
sured by questionnaire using the SF-36 scale [18] (range,
0–100): ‘low’ was deﬁned as a score \82 and C82 was
considered ‘high’. All statistical tests were two-sided with
a signiﬁcance level set at 0.05. Statistical analyses were
performed using SAS software (version 9.1; SAS Insti-
tute, Inc., Cary NC).
Results
The ﬂow of participants through the trial has been reported
elsewhere [6]. Brieﬂy, we assessed 3,454 women for eli-
gibility and 320 women were randomized with 165 women
from Edmonton and 155 from Calgary. We had nine
women withdraw from the study and provide no follow-up
data. For these analyses, we had 153 exercisers and 154
controls with complete data. Descriptive statistics for
baseline and 12-month levels of sex hormones, SHBG and
insulin levels, and all anthropometric measures have been
reported previously [6–8], and only a summary is provided
here (Table 1).
Women randomized to the exercise and control arms
were similar on all demographic, anthropometric, and
lifestyle characteristics. Our study population had a mean
age of 61 years, were overweight (mean BMI = 29), rel-
atively healthy and ﬁt (VO2max was 27 mL/kg/min), inac-
tive (11 MET-hours/week of recreational activity in the
year prior to the study), mainly Caucasian (91% white),
married (74%), and fairly well educated (67% greater than
high school education).
Mediation
In the present analysis, adjustment for change in percent
and total body fat attenuated intervention effects on total
estradiol concentrations, but change in intra-abdominal fat
area did not (Table 2). For free estradiol, the attenuation
was slightly stronger with adjustment for overall body fat
change than for intra-abdominal fat change. Intervention
effects on SHBG change were attenuated to almost null
with adjustment for total and percent body fat and attenu-
ated to a slightly lesser extent with adjustment for intra-
abdominal fat change (Table 2). Adjusting for insulin
change did not inﬂuence the intervention effect. In these
same models, however, insulin change was associated with
SHBG change when adjusting for intervention effects
(p for insulin = 0.001). In exploratory analyses, SHBG
change and insulin change were signiﬁcantly inversely
correlated in controls (p = 0.003), but not in exercisers
(p = 0.304).
Moderation
The statistical signiﬁcance of the interaction term between
intervention group and each potential moderator is shown
in Table 3.
No statistically signiﬁcant moderation by baseline
characteristics was found for estradiol and estrone changes.
For SHBG changes, the intervention effect was statistically
signiﬁcantly higher among women with lower baseline
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123Table 1 Baseline
characteristics of randomized
participants in the ALPHA
Trial, Alberta, Canada,
2003–2007, n = 320
Baseline characteristics Exercisers (n = 160) Controls (n = 160)
Mean ± SD Mean ± SD
Age (yrs) 61.2 ± 5.4 60.6 ± 5.7
Body composition measurements
Body mass index (kg/m
2) 29.1 ± 4.5 29.2 ± 4.3
Intra-abdominal fat area (cm
2) 101.4 ± 55.4 103.2 ± 56.0
Total body fat (kg) 30.9 ± 8.2 31.3 ± 8.6
Percent body fat 42.2 ± 4.9 42.4 ± 5.7
n (%) n (%)
Full-time employment 82 (55) 79 (51)
Education ([high school) 112 (70) 102 (64)
Median (IQR) Median (IQR)
Sex hormone concentration
Estradiol (pg/mL) 9.0 (7.0–12.0) 10.0 (7.0–14.0)
Estrone (pg/mL) 32.0 (24.0–44.0) 32.0 (22.5–44.5)
Sex hormone–binding globulin (nmol/L) 41.5 (30.0–57.0) 39.5 (28.0–51.5)
Androstenedione (pg/mL) 576 (434–779) 547 (417–736)
Testosterone (ng/dL) 24.3 (16.8–32.8) 23.3 (17.5–32.4)
Free estradiol (pg/mL) 0.23 (0.17–0.31) 0.24 (0.18–0.36)
Free testosterone (ng/dL) 0.36 (0.24–0.48) 0.36 (0.25–0.49)
Metabolic hormone concentration
Insulin (lIU/mL) 6.2 (3.8–9.5) 5.7 (3.4–8.9)
Table 2 Exercise intervention effects on estradiol and sex hormone–binding globulin before and after adjustment for hypothesized mediators
Outcome Before adjustment Hypothesized
mediator
After adjustment
Treatment effect ratio
of Exercise/Control (95% CI)
a
Treatment Effect Ratio
of Exercise/Control (95% CI)
a
p for mediator
b
Estradiol
0.93 (0.88–0.98) Percent body fat 0.95 (0.90–1.00) 0.005
Total body fat 0.95 (0.90–1.00) 0.005
Intra-abdominal fat area 0.93 (0.89–0.99) 0.176
Sex hormone–binding globulin
1.04 (1.02–1.07) Percent body fat 1.01 (0.98–1.03) \.001
Total body fat 1.01 (0.98–1.03) \.001
Intra-abdominal fat area 1.02 (0.99–1.05) \.001
Insulin 1.04 (1.01–1.06) 0.001
Free estradiol
0.91 (0.87–0.96) Percent body fat 0.94 (0.89–1.00) \.001
Total body fat 0.94 (0.89–1.00) \.001
Intra-abdominal fat area 0.93 (0.88–0.98) 0.051
a The treatment effect ratio was calculated from a general linear model for each biomarker outcome, estimating a parameter whose anti-
logarithm corresponds to the ratio of adjusted geometric means of the biomarker for the exercise intervention group over the control group: this
ratio was assumed to be common at 6 months and 12 months postrandomization. A ratio \1.0 indicates lower hormone or SHBG levels in
exercisers relative to controls at 6 and 12 months; a ratio[1.0 indicates a higher hormone or SHBG levels in exercisers; and a ratio equal to 1.0
indicates no difference between exercisers and controls. The model after-adjustment has one more covariate: change of hypothesized mediator at
6 and 12 months, compared to the model before-adjustment
b P value for the association between mediator and outcome after adjustment for intervention assignment
Sample size N: exercise group, baseline = 160, 6 month = 154, 12 month = 154; control group, baseline = 160, 6 month = 154,
12 month = 156
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123Table 3 Exercise intervention effects on sex hormones, stratiﬁed by potential moderators
Moderator
a n
b Treatment effect ratio
c (95% CI)
Level Estradiol Estrone Testosterone SHBG
Physical ﬁtness (VO2max)
B27.5 mL/kg/min 82/80 0.98 (0.92–1.04) 0.98 (0.92–1.05) 0.97 (0.92–1.03) 1.06 (1.02–1.09)
[27.5 77/79 0.89 (0.82–0.96) 0.99 (0.93–1.05) 1.01 (0.95–1.07) 1.03 (0.99–1.07)
p
e 0.573 0.175 0.035 0.005
Age
B60 years 73/81 0.91 (0.83–0.99) 1.01 (0.95–1.07) 1.03 (0.97–1.10) 1.04 (1.00–1.08)
[60 87/78 0.96 (0.91–1.02) 0.96 (0.90–1.03) 0.95 (0.90–1.01) 1.04 (1.01–1.08)
p
e 0.712 0.200 0.038 0.480
Time since menopause
\10 years 80/69 0.91 (0.84–0.99) 1.02 (0.96–1.08) 1.02 (0.96–1.08) 1.05 (1.02–1.09)
C10 78/90 0.96 (0.91–1.02) 0.96 (0.90–1.03) 0.95 (0.90–1.00) 1.04 (1.00–1.08)
p
e 0.673 0.776 0.609 0.477
Previous HRT use
Yes 75/71 0.92 (0.87–0.99) 0.97 (0.90–1.04) 0.96 (0.90–1.02) 1.02 (0.98–1.06)
No 84/88 0.94 (0.87–1.01) 1.00 (0.95–1.06) 1.01 (0.95–1.07) 1.07 (1.03–1.10)
p
e 0.754 0.480 0.326 0.149
Self-rated health
d
Low 88/76 0.93 (0.86–1.01) 1.01 (0.94–1.07) 0.97 (0.91–1.03) 1.05 (1.02–1.09)
High 71/81 0.92 (0.86–0.98) 0.97 (0.92–1.04) 1.02 (0.96–1.08) 1.04 (1.00–1.08)
p
e 0.516 0.441 0.968 0.923
Past year recreational activity
\7 MET–h/week 87/74 0.88 (0.82–0.95) 0.96 (0.90–1.02) 0.95 (0.90–1.01) 1.05 (1.01–1.09)
C7 73/85 0.97 (0.90–1.05) 1.01 (0.94–1.07) 1.02 (0.96–1.09) 1.04 (1.00–1.08)
p
e 0.642 0.656 0.637 0.508
Body mass index
\28.7 kg/m
2 80/77 0.95 (0.87–1.03) 1.04 (0.97–1.11) 1.03 (0.97–1.09) 1.03 (0.99–1.07)
C28.7 80/82 0.91 (0.86–0.96) 0.94 (0.89–1.00) 0.95 (0.90–1.01) 1.06 (1.02–1.10)
p
e 0.714 0.066 0.179 0.586
Estradiol
\10 pg/mL 86/70 0.97 (0.90–1.04)
C10 74/89 0.90 (0.84–0.97)
p
e 0.935
Estrone
\32 pg/mL 87/85 1.01 (0.95–1.08)
C32 73/74 0.96 (0.90–1.02)
p
e 0.180
Testosterone
\24 ng/dL 77/82 0.99 (0.93–1.06)
C24 83/77 0.99 (0.93–1.04)
p
e 0.497
SHBG
\40 nmol/L 76/85 1.06 (1.02–1.10)
C40 84/74 1.03 (0.99–1.06)
p
e 0.764
SHBG sex hormone–binding globulin
a Level of potential moderator at baseline
b Number of exercisers/number of controls
c The treatment effect ratio was calculated from a general linear model for each biomarker outcome, estimating a parameter whose anti-logarithm corresponds to the ratio of
adjusted geometric means of the biomarker for the exercise intervention group over the control group: this ratio was assumed to be common at 6 months and 12 months
postrandomization. A ratio\1.0 indicates lower hormone or SHBG levels in exercisers relative to controls at 6 and 12 months; a ratio[1.0 indicates higher hormone or SHBG
levels in exercisers; and a ratio equal to 1.0 indicates no difference between exercisers and controls
d Self-rated health measured by self-administered questionnaire using the SF-36 scale (range, 0–100) where low was a score of\82 and high was C82
e Statistical signiﬁcance of the interaction term between intervention group and the potential moderator. Note that all moderators except for previous HRT use were treated as
continuous variables when calculating this p value for heterogeneity
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(continuous, p = 0.005). For testosterone, intervention
effects were comparable across dichotomized subgroups;
however, ﬁtness (continuous, p = 0.035) and age (contin-
uous, p = 0.038) appeared to moderate the intervention
effect in general linear models.
In exploratory analyses, no baseline factor examined as
a moderator was signiﬁcantly correlated with adherence
(measured as average weekly duration of exercise) among
exercisers.
Discussion
This intervention study investigated potential factors that
may mediate and moderate the relation between endoge-
nous sex hormone changes and physical activity among
postmenopausal women. This important research question
has not been formally examined in previous randomized
trials. We found that exercise effects on SHBG and estra-
diol change were attenuated with adjustment for total and
percent body fat change and somewhat attenuated with
adjustment for intra-abdominal fat change. Intervention
effects on SHBG levels were unaffected by adjustment for
insulin change. Baseline physical ﬁtness that appeared to
moderate the intervention effects on testosterone and
SHBG levels and age seemed to moderate the intervention
effects on testosterone levels.
Overall fat loss appeared to mediate SHBG change
since, in general linear models, SHBG change was asso-
ciated with changes in all measures of adiposity, and
decreases in percent body fat, total body fat, and intra-
abdominal fat each explained most of the total effect of
exercise on SHBG change. In another RCT of postmeno-
pausal women, McTiernan et al. [19] similarly found that
the greatest 12-month increases in SHBG levels occurred
in the subgroup of women who lost [2% body fat,
regardless of group assignment. A recent RCT by Monn-
inkhof et al. [20] did not ﬁnd a signiﬁcant effect of exercise
on SHBG change over 12 months, possibly because the
average decrease in fat mass among exercisers (0.8 kg) was
lower than in our study (2.4 kg; ref [8]).
We explored insulin reduction as a possible mediator of
exercise-induced increases in SHBG levels since insulin
lowers SHBG synthesis in the liver [5]. We found that
although exercisers experienced a greater decrease in
serum insulin concentrations than controls [7], this change
did not explain the intervention effect for SHBG. Yet, in
exploratory analyses, insulin change correlated with SHBG
change in the control group (but not exercisers) and was
signiﬁcantly associated with SHBG change after control-
ling for intervention effects. Overall, these analyses imply
that while insulin changes may have altered SHBG con-
centrations in some women in the trial, this change does
not explain why SHBG changes were greater for exercisers
than for controls.
Relatively consistent RCT evidence now points to fat
loss as a mediator of exercise-induced estradiol changes.
From stratiﬁed analyses, McTiernan et al. [19] concluded
that combined exercise and fat loss of at least 0.5% may be
required to decrease total and free estradiol concentrations;
exercise without this level of fat loss did not affect estradiol
concentrations. Monninkhof et al. [20] found complete
attenuation of an exercise effect on free estradiol levels
after adjusting for body fat change, similarly implicating a
fat loss mechanism. Our adjusted models showed that
overall body fat loss and exercise contributed indepen-
dently to free and total estradiol changes over 12 months;
only a portion of the total effect of the intervention on
estradiol change was explained by fat loss. We also found
that intra-abdominal fat area did not appear to mediate total
estradiol changes, which is of interest to note given that
intra-abdominal fat in postmenopausal women relates
adversely to adipokine and inﬂammation levels [21], which
are causally related to several chronic diseases [22, 23]. In
a comprehensive 2007 report on cancer prevention [2],
overall body fatness and abdominal fatness were
concluded to be ‘‘convincingly’’ and ‘‘probably’’ associated
with an increased risk of postmenopausal breast cancer,
respectively.
From a biologic perspective, exercise could lower
estradiol concentrations in a variety of ways postmeno-
pause, with loss of body fat proposed as a key mechanism.
After menopause, adipose tissue serves as a reservoir of
estrogen biosynthesis [24, 25]. Furthermore, several blood
biomarkers that occur at higher levels in overweight and
obese states such as leptin [26] and IL-6 and TNF-a [27]
may induce or stimulate this biosynthesis in some women
[28]. It is also possible that adiposity change was merely a
surrogate marker of the true mediator of estradiol (and
SHBG) changes. Although error in measurement of adi-
posity change could explain why we did not ﬁnd that it
wholly mediated exercise-induced estradiol changes, the
use of valid and reliable measures makes this possibility
less plausible. Mechanisms whereby exercise could affect
estradiol levels independently of fat loss are as of yet
unknown.
To our knowledge, no previous RCT in older women has
formally tested moderation of exercise-induced SHBG or
sex hormone changes. However, RCTs of 12-month aero-
bic exercise interventions described by McTiernan et al.
[29] and Irwin et al. [30] explored potential moderators of
adiposity change, which is relevant to this discussion.
Neither McTiernan et al. [29], studying 100 women with a
mean age of 54 years, nor Irwin et al. [30], studying 173
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123postmenopausal women, found statistically signiﬁcant
effect modiﬁcation by baseline BMI or age. Although we
found evidence of moderating effects of age and baseline
ﬁtness on testosterone changes, the magnitude of this
moderation did not appear to be great since treatment effect
ratios were close to 1.0 in subgroups of these characteris-
tics and not statistically signiﬁcant. The strongest evidence
of moderation was for baseline ﬁtness level and SHBG
change, in which intervention effects on SHBG appeared to
be stronger in women who were less ﬁt at baseline.
Exploratory analyses suggested that effect modiﬁcation did
not seem to be explained by differences in adherence but
could be explained by differences in ﬁtness change or
another factor for which ﬁtness change may be a surrogate.
Women with lower baseline ﬁtness level experienced
greater improvements in ﬁtness over the 12-month
intervention.
There are several limitations to our analyses. First, we
did not address all factors that could theoretically impact
individual responsiveness to exercise (e.g., genotype) in
our moderators analysis. Further limitations apply speciﬁ-
cally to the analysis of mediators [31]. For example,
mediation might differ across subgroups of exercising
women, but we did not have the power to explore this
possibility within our data. Our ﬁndings may not be gen-
eralizable to all postmenopausal women as our study
population was free of any major co-morbidities, pre-
dominantly Caucasian and educated, and included normal
weight women as well as overweight and obese women
[6, 8].
In conclusion, these analyses suggest possible mediation
of exercise-induced changes in estradiol and SHBG con-
centrations by loss of overall body fat. Our data further
imply that other biologic mechanisms related to exercise
were also driving estradiol changes, potentially lowering
postmenopausal breast cancer risk, and thus, there is a need
to identify those mechanisms. While strong biologic
plausibility supports mediation of estradiol changes
through fat loss, the understanding of how fat loss relates to
SHBG concentrations is less clear. Whether fat loss
mediates those changes, or represents a surrogate marker of
the true mediator, warrants further study. We found no
evidence supporting insulin change as a mediator of exer-
cise-induced changes in SHBG levels. We identiﬁed
baseline physical ﬁtness and age as possible moderators of
exercise-induced testosterone and SHBG changes. This
research provides compelling evidence among postmeno-
pausal women of how the relation between physical
activity and endogenous sex hormone changes is mediated
by body fat loss and the ﬁrst evidence of moderation by
physical ﬁtness and age. Future research will be needed in
other populations to corroborate and expand these latter
ﬁndings.
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